Latest News
Nov 7, 2018
Genentech's Immunology/Infectious Disease Deal Maker On Following The Science

Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering.

When reflecting on the licensing deals inked this...

Nov 2, 2018
Microbiotica Wins Life Sciences Company of the Year at Cambridge Independent Awards

Cambridge, UK, 2 November 2018 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been named Life Sciences Company of the Year at the...

Oct 30, 2018
Microbiotica Participates in Microbiome Panel Discussion at this year’s Bio-Europe®

Cambridge, UK, 30 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it will join the microbiome panel at this year’s BIO-Europe®,...

Oct 24, 2018
Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund

·     Seventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life Capital™ and strengthens Microbiotica’s Board with microbiome...

Jun 18, 2018
Microbiotica Collaborates with University of Adelaide to Develop a Novel Microbial Therapy for Ulcerative Colitis

Cambridge, UK, 18 June 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its...

Jun 6, 2018
Microbiotica Enters into Microbiome Collaboration with Genentech
  • Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline
  • Utilises...
May 22, 2018
Microbiotica to Present at Top Microbiome Conferences

Cambridge, UK, 22 May 2018 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June.

...
Oct 26, 2017
Microbiotica to Participate in Microbiome Panel at BIO-Europe®

Cambridge, UK, 25th October 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the...

Oct 11, 2017
Microbiotica Celebrates Successful First Year with Third Award Win

Company receives ‘Best Start-up Biotech’ at OBN Awards

Cambridge, UK, 11 October 2017 – Microbiotica, a leading player in microbiome-based...

Sep 18, 2017
Microbiotica Wins Biotech and Money’s ‘Life Science Spin-out of the Year’

Cambridge, UK, 18 September 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it was chosen as the winner of the ‘Life Science Spin-out of the...

Sep 18, 2017
Microbiotica to Present at Leading Microbiome Summit

Cambridge, UK, 18 September 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that CEO, Dr Mike Romanos, will present at the Annual Microbiome Summit:...

Aug 9, 2017
Microbiotica Shortlisted for 2017 OBN Awards ‘Best Start-up Biotech Company’

Cambridge, UK, 9 August 2017 - Microbiotica, a leading player in microbiome-based therapeutics, is delighted to be announced that it has been selected as a finalist in the ‘Best Start-up...

Jul 13, 2017
Microbiotica Wins One Nucleus Summer BioNewsRound Award

Cambridge, UK, 13 July 2017 – Microbiotica, a leading player in microbiome-based therapeutics, is pleased to announce that it was voted as the winner of the Summer 2017 BioNewsRound Award at...

Jun 26, 2017
Microbiotica Shortlisted for Biotech and Money’s ‘Life Science Spin-out of the Year’

Cambridge, UK, 26 June 2017

Microbiotica, a leading player in microbiome-based therapeutics, is delighted to announce that it has been shortlisted for the ‘Life Science Spin-out of...

Jun 20, 2017
Microbiotica to Present at Microbiome Drug Development Summit

27-29 June 2017, Boston

Cambridge, UK, 20 June 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that its Chief Scientific Officer Dr Trevor Lawley...

May 9, 2017
Microbiotica Appoints John Shields as Non-Executive Director

Microbiotica, the spin-out company from the UK’s Wellcome Trust Sanger Institute (Sanger Institute), is pleased to announce the appointment of Dr John Shields as a non-executive...

Dec 19, 2016
Cambridge Innovation Capital plc and IP Group plc announce the creation of Wellcome Trust Sanger Institute spin-out company, Microbiotica

Based on ground-breaking research at the Wellcome Trust Sanger Institute into the role of the human microbiome in disease

Goal is to create the world’s leading company focused on microbiome biology...


 Contacts:

Microbiotica

 Instinctif Partners

 (media enquiries)

Rowena Gardner

Sue Charles / Gemma Harris

E: rgardner@microbiotica.com

E: microbiotica@instinctif.com

T: +44 (0) 1223 786063

T: + 44 (0) 20 7866 7860

 

Upcoming Events
JP Morgan
Jan 7 to Jan 10, 2019
San Francisco, California
Microbiome Movement - Drug Development Summit Europe 2019
Jan 28 to Jan 30, 2019
Paris, France
More Information
ECCMID
Apr 13 to Apr 16, 2019
Amsterdam, Netherlands
Past Events
Exploring Human Host-Microbiome Interactions in Health and Disease
Dec 5 to Dec 7, 2018
Wellcome Genome Campus, Cambridge, UK
More Information
Bio-Europe®
Nov 5 to Nov 7, 2018
Copenhagen, Denmark
More Information
The Royal Society
Oct 5, 2018
London
More Information
IP Group- Global Deep Tech Forum
Sep 18 to Sep 20, 2018
Hong Kong and Shanghai
Microbiome Drug Development
Jun 20 to Jun 22, 2018
Boston
Microbiome Invest
May 23, 2018
London
More Information
Microbiome Drug Development Summit Paris 2018
Jan 29 to Jan 31, 2018
Paris
Norwich Research Park Leadership Session at Genesis 2017- Collaborating with the Microbiome
Dec 14, 2017
London